Tobramycin Ophthalmic Solution recalled for failed quality specifications
Alembic Pharmaceuticals is recalling 82,400 bottles of Tobramycin Ophthalmic Solution nationwide because the product failed to meet impurities and degradation specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall for failed quality specifications with no reported illnesses or injuries. Class III recalls are typically lower severity, and this represents a precautionary quality-control recall.
Plain-English summary
Alembic Pharmaceuticals, Inc. is recalling Tobramycin Ophthalmic Solution USP 0.3%, 5 mL bottles because the product failed to meet impurities and degradation specifications. The recall affects 82,400 bottles distributed nationwide in the United States. The affected lots are AMR103 (expiration 10/2023) and AMR201 (expiration 06/2024). The FDA has classified this as a Class III recall.
Persons who have purchased or received affected lots should contact Alembic Pharmaceuticals, their pharmacist, or their healthcare provider for more information about this recall. Patients currently taking medication from affected lots should consult their healthcare provider about whether to continue use of their current supply.
The recalled product
- Product
- TOBRAMYCIN OPHTHALMIC SOLUTION (TOBRAMYCIN OPHTHALMIC SOLUTION)
- Brand
- TOBRAMYCIN OPHTHALMIC SOLUTION
- Manufacturer
- ALEMBIC PHARMACEUTICALS, INC.
- Category
- Drug — Ophthalmic
- Affected units
- 82,400
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: AMR103
- Exp: 10/2023
- Lot#: AMR201
- Exp: 06/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · ALEMBIC PHARMACEUTICALS, INC.
See all →- ModeratePrescription Diclofenac Sodium Topical Solution Recalled for Defective Delivery System
FDA (Drugs) · 2023-08-02
Same hazard · degradation
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateAniara 5-PLASMA Bivalirudin Calibrator Recalled for Stability Issues
FDA (Devices) · 2026-08-12
- Moderate5-PLASMA Bivalirudin Control Model 5D-44905 Recalled Due to Stability Issues
FDA (Devices) · 2026-08-12
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15